Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00936936 · ClinicalTrials.gov registry record · Phase 2
High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
A Phase 2 study of Testicular Cancer, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 2
- Study locations
NCT00936936 is a Phase 2 study of Testicular Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 64 participants, below the 89-participant average among 11 other Testicular Cancer trials with a reported enrollment target (28% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00936936, a Phase 2 study of Testicular Cancer, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical research study is to learn if 2 cycles of high-dose chemotherapy can help to control germ-cell tumors. The first cycle of chemotherapy will include the drugs gemcitabine, docetaxel, melphalan, and carboplatin. The second cycle of chemotherapy will include the drugs ifosfamide, carboplatin, and etoposide. The safety of these drug combinations will also be studied. This is an investigational study. Gemcitabine, docetaxel, melphalan, ifosfamide, carboplatin, and etoposide are all FDA-approved and commercially available for the treatment of germ-cell tumors. Up to 67 patients will be enrolled in this study.
Conditions Studied
Interventions
- DRUG Melphalan
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Mesna
- DRUG Gemcitabine
Study Locations (2)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2009-06-02 |
| Est. Completion | 2024-01-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00936936
The ClinicalTrials.gov registry entry for NCT00936936 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 89-participant average among 11 other Testicular Cancer trials with a reported enrollment target (28% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Testicular Cancer appearing as the primary indexed condition, and to 5 interventions - of which Melphalan is the first listed.
NCT00936936 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Washington.
Frequently Asked Questions
What is clinical trial NCT00936936 about?
NCT00936936 is a clinical study titled "High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors". The goal of this clinical research study is to learn if 2 cycles of high-dose chemotherapy can help to control germ-cell tumors. The first cycle of chemotherapy will include the drugs gemcitabine, docetaxel, melphalan, and carboplatin. The second cycle of chemotherapy will include the drugs ifosfami...
What is the current status of trial NCT00936936?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2009-06-02. Estimated completion is 2024-01-11.
What conditions does trial NCT00936936 study?
This clinical trial studies the following conditions: Testicular Cancer.
What interventions are being tested in trial NCT00936936?
The interventions under investigation include: Melphalan (DRUG), Carboplatin (DRUG), Docetaxel (DRUG), Mesna (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00936936?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00936936 being conducted?
This trial has 2 study locations across Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Testicular Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy
RECRUITING · Phase 2
-
Patient Reported Experiences With Sparing External Oblique Fascia Vs Standard Inguinal Orchiectomy
RECRUITING · NA
-
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
RECRUITING · Phase 1
-
Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.
RECRUITING · Phase 3
-
A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors
RECRUITING · NA
-
A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.